KYMR on Nasdaq
Kymera Therapeutics
Biopharmaceutical company.1
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with SANGAMO THERAPEUTICS, INC, Voyager Therapeutics (United States) or Editas Medicine, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-891.1%Operating margin4
-794.0%Net margin4
-16.7%Revenue growth, 20254
-19.7%Return on equity4
-$234.3MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue11¢$39.2M
- Research and development89¢$316.6M
Out of $39.2M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration revenue | $39.2M | $47.1M | $78.6M |
| Research and development | $316.6M | $240.2M | $189.1M |
| General and administrative | $68.2M | $63.5M | $55.0M |
| Impairment of long-lived assets | $3.9M | $4.9M | $0 |
| Total operating expenses | $388.6M | $308.7M | $244.1M |
| Loss from operations | -$349.4M | -$261.6M | -$165.5M |
| Interest and other income | $38.4M | $38.0M | $18.8M |
| Interest and other expense | -$370.0K | -$249.0K | -$196.0K |
| Total other income | $38.0M | $37.8M | $18.6M |
| Net loss | -$311.4M | -$223.9M | -$147.0M |
| Unrealized gain (loss) on marketable securities | $3.3M | -$933.0K | $4.4M |
| Total comprehensive loss | -$308.1M | -$224.8M | -$142.6M |
| Net loss attributable to common stockholders | -$311.4M | -$223.9M | -$147.0M |
| Net loss per share, basic | -$3.69 | -$2.98 | -$2.52 |
| Net loss per share, diluted | -$3.69 | -$2.98 | -$2.52 |
| Total weighted average common stock outstanding, basic and diluted | 84.5M shares | 75.0M shares | 58.4M shares |
| Total weighted average common stock outstanding, basic and diluted | 84.5M shares | 75.0M shares | 58.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $357.0M | $120.3M | $110.0M | |
| Marketable securities (Note 4) | $491.3M | $368.5M | ||
| Prepaid expenses and other current assets | $22.9M | $21.5M | ||
| Total current assets | $871.2M | $510.3M | ||
| Marketable securities, non-current (Note 4) | $771.2M | $362.2M | ||
| Property and equipment, net (Note 6) | $43.2M | $50.5M | ||
| Right-of-use assets, operating leases | $42.4M | $47.4M | ||
| Other non-current assets | $9.1M | $1.9M | ||
| Restricted cash | $5.8M | $5.8M | ||
| Total assets | $1.7B | $978.0M | ||
| Accounts payable | $4.0M | $6.0M | ||
| Accrued expenses (Note 8) | $42.3M | $34.9M | ||
| Deferred revenue | $22.9M | $13.6M | ||
| Operating lease liabilities | $11.9M | $11.6M | ||
| Finance lease liabilities | $1.8M | $1.5M | ||
| Other current liabilities | $242.0K | $223.0K | ||
| Total current liabilities | $83.2M | $67.8M | ||
| Deferred revenue, net of current portion | $11.4M | $0 | ||
| Operating lease liabilities, net of current portion | $67.0M | $72.4M | ||
| Finance lease liabilities, net of current portion | $1.5M | $2.2M | ||
| Total liabilities | $163.1M | $142.4M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 81,323,532 and 64,890,193 shares issued and outstanding at December 31, 2025 and 2024, respectively | $8.0K | $7.0K | ||
| Additional paid-in capital | $2.6B | $1.6B | ||
| Accumulated deficit | -$1.1B | -$754.6M | ||
| Accumulated other comprehensive income (loss) | $1.8M | -$1.5M | ||
| Total stockholders' equity | $1.6B | $835.6M | $395.0M | $490.2M |
| Total liabilities and stockholders' equity | $1.7B | $978.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, authorized | 150.0M shares | 150.0M shares | ||
| Common stock, issued | 81.3M shares | 64.9M shares | ||
| Common Stock, outstanding | 81.3M shares | 64.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $357.0M | $120.3M | $110.0M | |
| Marketable securities (Note 4) | $491.3M | $368.5M | ||
| Prepaid expenses and other current assets | $22.9M | $21.5M | ||
| Total current assets | $871.2M | $510.3M | ||
| Marketable securities, non-current (Note 4) | $771.2M | $362.2M | ||
| Property and equipment, net (Note 6) | $43.2M | $50.5M | ||
| Right-of-use assets, operating leases | $42.4M | $47.4M | ||
| Other non-current assets | $9.1M | $1.9M | ||
| Restricted cash | $5.8M | $5.8M | ||
| Total assets | $1.7B | $978.0M | ||
| Accounts payable | $4.0M | $6.0M | ||
| Accrued expenses (Note 8) | $42.3M | $34.9M | ||
| Deferred revenue | $22.9M | $13.6M | ||
| Operating lease liabilities | $11.9M | $11.6M | ||
| Finance lease liabilities | $1.8M | $1.5M | ||
| Other current liabilities | $242.0K | $223.0K | ||
| Total current liabilities | $83.2M | $67.8M | ||
| Deferred revenue, net of current portion | $11.4M | $0 | ||
| Operating lease liabilities, net of current portion | $67.0M | $72.4M | ||
| Finance lease liabilities, net of current portion | $1.5M | $2.2M | ||
| Total liabilities | $163.1M | $142.4M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 81,323,532 and 64,890,193 shares issued and outstanding at December 31, 2025 and 2024, respectively | $8.0K | $7.0K | ||
| Additional paid-in capital | $2.6B | $1.6B | ||
| Accumulated deficit | -$1.1B | -$754.6M | ||
| Accumulated other comprehensive income (loss) | $1.8M | -$1.5M | ||
| Total stockholders' equity | $1.6B | $835.6M | $395.0M | $490.2M |
| Total liabilities and stockholders' equity | $1.7B | $978.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, authorized | 150.0M shares | 150.0M shares | ||
| Common stock, issued | 81.3M shares | 64.9M shares | ||
| Common Stock, outstanding | 81.3M shares | 64.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$311.4M | -$223.9M | -$147.0M |
| Stock-based compensation expense | $59.9M | $55.0M | $43.1M |
| Impairment of long-lived assets | $3.9M | $4.9M | $0 |
| Depreciation and amortization | $8.3M | $7.4M | $3.6M |
| Premiums and discounts on available for sale marketable securities | -$8.9M | -$14.0M | -$5.2M |
| Prepaid expenses and other assets | -$2.4M | -$8.9M | -$2.0M |
| Accounts receivable | $0 | $15.0M | -$15.0M |
| Contract asset | $947.0K | $2.8M | -$1.2M |
| Accounts payable | -$2.0M | -$307.0K | $2.0M |
| Accrued expenses and other current liabilities | $7.4M | $4.2M | $3.2M |
| Deferred revenue | $20.8M | -$41.1M | -$8.6M |
| Operating lease right-of-use assets | $2.7M | $2.5M | $4.8M |
| Operating lease liabilities | -$5.0M | $1.9M | $18.6M |
| Other non-current assets | -$7.2M | $168.0K | $909.0K |
| Other non-current liabilities | $18.0K | -$310.0K | -$28.0K |
| Net cash used in operating activities | -$232.9M | -$194.5M | -$102.8M |
| Purchase of property and equipment, net | -$1.4M | -$12.8M | -$34.5M |
| Purchase of marketable securities | -$1.0B | -$901.2M | -$189.2M |
| Maturities of marketable securities | $488.0M | $510.0M | $363.5M |
| Net cash provided by (used in) investing activities | -$521.1M | -$404.1M | $139.9M |
| Issuance of common stock and accompanying pre-funded warrants from January 2024 public offering, net of issuance costs of $14.9 million | $0 | $301.4M | $0 |
| Proceeds from issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million | $0 | $48.7M | $0 |
| Issuance of common stock and accompanying pre-funded warrants from August 2024 public offering, net of issuance costs of $12.2 million | $0 | $246.5M | $0 |
| Issuance of common stock from December 2025 public offering, net of issuance costs of $36.2 million | $656.2M | $0 | $0 |
| Proceeds from stock option exercises | $61.6M | $11.8M | $2.9M |
| Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million | $272.7M | $0 | $0 |
| Proceeds from employee stock purchase plan | $1.7M | $2.0M | $1.4M |
| Payments on financing leases | -$1.5M | -$1.6M | -$76.0K |
| Net cash provided by financing activities | $990.7M | $608.9M | $4.2M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $236.8M | $10.3M | $41.3M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $0 | $0 | $48.8M |
| Cash paid for interest | $312.0K | $206.0K | $162.0K |
| Purchases of property and equipment through finance and lease liabilities | $1.0M | $2.7M | $0 |
| Property and equipment purchases included in accounts payable and accrued expenses | $80.0K | $60.0K | $4.0M |
| Issuance of common stock under ATM | $1.2M | $1.2M | $1.2M |
| Private placement, net of issuance costs | $14.9M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Kymera Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerNello Mainolfi Aug 20, 2020 to now12
- PresidentNello Mainolfi Aug 20, 2020 to Aug 21, 202012
- Chief financial officerBruce N. Jacobs Aug 20, 2020 to now13
- Chief operating officerJeremy G. Chadwick May 22, 2023 to now14
Board members and other officers (23)
- Chief Medical OfficerTerence Rooney Jul 27, 2026 to now15
- Chief Business OfficerNoah Goodman Apr 9, 2025 to now16
- Chief Business OfficerElaine Caughey Jun 21, 2021 to Mar 3, 202317
- Chief Medical OfficerJared Gollob Aug 20, 2020 to now18
- Chief Scientific OfficerRichard Chesworth Aug 20, 2020 to Aug 27, 202119
- Board memberFelix Baker Apr 1, 2024 to now20
- Board memberJulian Baker Apr 1, 2024 to now20
- Board memberL.p. 667 Apr 1, 2024 to now20
- Board memberMark N. Lampert Jan 13, 2023 to now21
- Board memberJohn Maraganore Jan 19, 2022 to now22
- Board memberLeigh Morgan Jul 8, 2022 to Jun 20, 202423
- Board memberVictor Sandor Nov 3, 2022 to now24
- Board memberElena Ridloff Mar 16, 2021 to now25
- Board memberAndrew Hedin Aug 20, 2020 to Aug 21, 202026
- Board memberBruce Booth Aug 20, 2020 to now27
- Board memberGorjan Hrustanovic Aug 20, 2020 to now28
- Board memberJeffrey W. Albers Aug 20, 2020 to now29
- Board memberJoanna Horobin Aug 20, 2020 to Jun 7, 202430
- Board memberNello Mainolfi Aug 20, 2020 to now12
- Board memberSteven Edward Hall Aug 20, 2020 to Jun 17, 202131
- Board memberPamela Esposito Sep 9, 2020 to now32
- General counselBrian Adams Sep 3, 2025 to now33
- General counselEllen Chiniara Jan 4, 2023 to Mar 3, 202534
Former names
- Kymera Therapeutics, Inc.Jun 22, 2020 to Oct 1, 20263
Timeline
Filings
505 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 63 major events, 211 insider forms, 58 large holders, 153 other. The latest 20:
- Oct 1, 2026144 EDGAR
- Oct 1, 20264 EDGAR
- Sep 8, 2026SCHEDULE 13G/A EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 27, 20264 EDGAR
- Jul 27, 20263 EDGAR
- Jul 27, 20268-K EDGAR
- Jul 7, 2026144 EDGAR
- Jul 7, 20264 EDGAR
- Jul 2, 2026144 EDGAR
- Jul 2, 20264/A EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20264 EDGAR
The 505 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 58 such filings since October 2021, the latest 10:
- Sep 8, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 2026SCHEDULE 13G/A
- Jun 26, 2026SCHEDULE 13D/A
- May 15, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 6, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 10, 2026SCHEDULE 13G/A
- Jan 8, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 12,349,256 | $1.4B | 0.1% | +649,306 |
| Baker Bros. Advisors LP | 8,657,242 | $992.7M | 5.0% | No change |
| Avoro Capital Advisors LLC | 7,474,747 | $857.1M | 7.7% | No change |
| BlackRock, Inc. | 5,538,210 | $635.1M | 0.0% | +477,334 |
| Bvf Inc/il | 3,872,052 | $444.0M | 11.4% | −1,630,658 |
| Wellington Management Group Llp | 3,675,028 | $421.4M | 0.1% | −214,659 |
| Vanguard Portfolio Management LLC | 2,992,193 | $343.1M | 0.0% | +118,137 |
| Siren, L.L.C. | 2,935,830 | $336.7M | 6.8% | −251,000 |
| Vanguard Capital Management LLC | 2,932,378 | $336.3M | 0.0% | +52,054 |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | $326.5M | 37.1% | −1,730,467 |
| State Street Corp | 2,737,226 | $313.9M | 0.0% | +347,459 |
| Geode Capital Management, LLC | 1,816,331 | $208.3M | 0.0% | +170,981 |
| Capital Research Global Investors | 1,388,881 | $159.3M | 0.0% | −284,394 |
| Goldman Sachs Group Inc | 1,187,333 | $136.2M | 0.0% | +298,924 |
| UBS Group AG | 1,007,777 | $115.6M | 0.0% | −16,075 |
| Driehaus Capital Management LLC | 919,233 | $105.4M | 0.6% | −124,350 |
| Merck & Co., Inc. | 772,165 | $88.5M | 16.8% | No change |
| Norges Bank | 757,246 | $86.8M | 0.0% | New |
| Federated Hermes, Inc. | 749,398 | $85.9M | 0.1% | +212,718 |
| Dimensional Fund Advisors LP | 745,152 | $85.4M | 0.0% | +152,273 |
| Frontier Capital Management Co LLC | 740,866 | $85.0M | 0.8% | −18,982 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 736,866 | $84.5M | 0.0% | −139,006 |
| Alliancebernstein L.P. | 981,521 | $81.8M | 0.0% | +93,486 |
| Holocene Advisors, LP | 636,579 | $73.0M | 0.2% | −200,180 |
| Northern Trust Corp | 581,907 | $66.7M | 0.0% | +87,468 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.kymeratx.com1
- WikidataQ113503520
- SEC EDGARCIK 1815442
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataKymera Therapeutics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARNoah Goodman, Chief Business Officer
- 17
- 18SEC EDGARJared Gollob, Chief Medical Officer
- 19
- 20SEC EDGARFelix Baker, Board member
- 21SEC EDGARMark N. Lampert, Board member
- 22SEC EDGARJohn Maraganore, Board member
- 23SEC EDGARLeigh Morgan, Board member
- 24SEC EDGARVictor Sandor, Board member
- 25SEC EDGARElena Ridloff, Board member
- 26SEC EDGARAndrew Hedin, Board member
- 27SEC EDGARBruce Booth, Board member
- 28SEC EDGARGorjan Hrustanovic, Board member
- 29SEC EDGARJeffrey W. Albers, Board member
- 30SEC EDGARJoanna Horobin, Board member
- 31SEC EDGARSteven Edward Hall, Board member
- 32SEC EDGARPamela Esposito, Board member
- 33SEC EDGARBrian Adams, General counsel
- 34SEC EDGAREllen Chiniara, General counsel